Neurobiological will fund a three-year joint research project, with $1.2 million in the first year and gains exclusive rights for $175,000.

Neurobiological Technologies and the Buck Institute for Age Research agreed to work together to develop a therapy for Alzheimer’s disease (AD). Besides this collaboration agreement, Neurobiological Technologies also entered an exclusive license deal related to a naturally occurring protein that has been shown in animals to reverse the symptoms of AD.

Under the terms of the agreement, Neurobiological Technologies will pay $175,000 for the license over a three-year period. The company will also fund the joint research program for up to three years. A total of $1.2 million will be paid in the first year for research.

The Buck is focusing on a naturally occurring protein that has reportedly been shown in cell culture and mice to inhibit the production of amyloid-b (AB) peptides while simultaneously facilitating the growth and preservation of nerve fibers in the brain.

This contract comes on the heels of another partnership formed in December 2007 for development of a drug for Huntington’s disease. 

Previous articleOneWorld Health, Amyris, and Sanofi-Aventis to Create a Complementary Source for Key Ingredient of Malaria Therapy
Next articlemiRNA Identified that Helps Skin Develop Protective Layer